Does ALT tell me anything about hepatic fat on a GLP-1 receptor agonist?

Setup, so nobody has to ask: ALT · a GLP-1 receptor agonist.

I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.

My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.

Why does this happen, and what would falsify the usual explanation?

Answering this needs the magnitude in multiples of the upper reference limit, because the thresholds that matter clinically are defined that way and not in absolute units.

Hy's law describes the combination that matters: transaminases above three times the upper limit together with bilirubin above twice the upper limit and no cholestatic explanation. That combination is a signal; isolated mild transaminase elevation is not.

To be exact about it, creatine kinase, alkaline phosphatase and bilirubin together tell you which compartment the abnormality is in, and ordering the transaminases alone throws that information away.

Population data show a substantial fraction of adults with mild transaminase elevation attributable to hepatic steatosis, which sets the base rate against which any new finding should be read.

Isolated mild elevation is common and usually improves with weight loss.

Start with the pattern. A hepatocellular pattern with alanine aminotransferase above aspartate aminotransferase points one way; a cholestatic pattern with alkaline phosphatase and gamma-glutamyl transferase points another.

An isolated result three weeks after starting anything is difficult to interpret. A baseline taken before starting makes the same result trivially interpretable, which is the argument for baselines.

Weight loss of ten per cent or more typically reduces transaminases substantially in people whose elevation was driven by hepatic fat, which is the majority of mild elevations in this population.

Nothing here is medical advice. An abnormal result needs somebody who can take a history and examine you.

Transaminases plus bilirubin plus alkaline phosphatase, or you have not measured enough to conclude anything.

edited 9 Oct 2025 by fib4_reader — tightened the wording; no substantive change

Before attributing anything to a compound, account for alcohol, muscle injury from new training, and any over-the-counter product being taken alongside.

Alanine aminotransferase is relatively liver-specific; aspartate aminotransferase is also present in muscle, heart and red cells. A raised AST with a normal ALT after heavy resistance training is usually muscle, and creatine kinase settles the question.

Laboratory-specific reference intervals for transaminases vary enough that cross-laboratory comparison of borderline values is unreliable.

The caveat is direct: rising liver enzymes with jaundice, dark urine or right-upper-quadrant pain is a same-day clinical problem, not a forum question.

New training, alcohol and over-the-counter products first. Then the interesting hypotheses.

In practice, this is one of the areas where the trend across several measurements is far more informative than any single result.

Reference upper limits around forty units per litre for ALT are conventional rather than physiological; several groups have argued for limits closer to thirty for men and twenty-five for women.

Hy's law and its variants are the standard framework for identifying drug-induced liver injury in trials and are why bilirubin is measured alongside transaminases rather than instead.

Research-use material of unknown content is an unquantifiable variable in any such attribution.

Get a baseline before you start anything, because it converts an uninterpretable result into an interpretable one for the cost of one blood draw.